Results 151 to 160 of about 7,551 (201)

Anti-hepatitis B virus effects of traditional Chinese medicine: Learning from clinical trials in the past twenty years. [PDF]

World J Hepatol
Feng X, Li NN, Liu GJ, An C, Liu C.
europepmc   +1 more source

Eight-year Results from Two Randomized Phase 3 Trials of Tenofovir Alafenamide for Chronic Hepatitis B Virus Infection in China. [PDF]

J Clin Transl Hepatol
Hou J, Ning Q, Duan Z, Chen Y, Xie Q, Zhang L, Wu S, Tang H, Li J, Lin F, Yang Y, Gong G, Luo Y, Chen Y, Abramov F, Yee LJ, Wang H, Mateo R, Yazdi T, Botros I, Chen C, Huang Y, Zhang M, Jia J.   +23 more
europepmc   +1 more source

Chronic hepatitis B in 2025: diagnosis, treatment and future directions. [PDF]

Clin Med (Lond)
Watson AG, Mulay AS, Gill US.
europepmc   +1 more source

Efficacy and safety of entecavir, peginterferon alfa-2b and GM-CSF combination therapy: the anchor randomized controlled trial. [PDF]

Hepatol Int
Wu D, Huang D, Peng S, Chen Y, Yang F, Zhang X, Fu L, Xu L, Jiang J, Zheng Q, Chen X, Liu Y, Dou X, Ma K, Xi D, Wang P, Sun L, He R, Tian Y, Yin P, Yan W, Han M, Ning Q.   +22 more
europepmc   +1 more source

Do the therapeutic vaccines hold hope for the treatment of hepatitis B? [PDF]

Hepatol Int
Yan Q, Fu X, Wang Y, Wang G.
europepmc   +1 more source

A retrospective comparative study of tenofovir alafenamide and tenofovir disoproxil fumarate in chronic hepatitis B patients: Renal and bone safety versus antiviral efficacy. [PDF]

Medicine (Baltimore)
Wang L, Pi G, Lu D, Wang Y, Sun W.
europepmc   +1 more source

Effects of Non-Alcoholic Fatty Liver Disease on Baseline Histology and 96-Week Entecavir Response in Treatment-Naïve Chronic Hepatitis B. [PDF]

Infect Drug Resist
Gu X, Yang W, Hu Y, Li Y, Zheng L, Jiang B.   +5 more
europepmc   +1 more source

Dades epidemiològiques, clíniques i tractament de pacients amb infecció crònica pel virus hepatitis b en l'àrea barcelonès nord i maresme [PDF]

, 2013
Morillas Cunill, Rosa Ma., Planas Vilà, Ramon, Riu Pons, Fausto, Universitat Autònoma de Barcelona. Departament de Medicina, Universitat Autònoma de Barcelona. Facultat de Medicina   +4 more
core  

Incidence and predictors of HBsAg loss following addition of pegylated interferon Alfa-2b in chronic hepatitis B patients suppressed by nucleos(t)ide analogues: a multicenter, prospective, cohort study. [PDF]

Virol J
Zhao J, Bian D, Xie D, Lv J, Lin L, Chen X, Zhang L, Feng B, Xu X, Lu F, Zheng S.   +10 more
europepmc   +1 more source